Lichen simplex chronicus is a chronic, inflammatory skin condition characterized by scaly ... Identifying the root cause/underlying condition and breaking the itch-scratch-itch cycle are most ...

Biopsy showed lichen simplex chronicus. There are no clinical manifestations ... Upper thighs, arm, and trunk responded extremely well after 10 treatments of UVB (about 1 month).

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

Nail biopsy: If lichen planus may be affecting one or more of your nails, your dermatologist will remove a small sample from the suspected area, so that it can be examined under a microscope. Not ...

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).

Nail biopsy: If lichen planus may be affecting one or more of your nails, your dermatologist will remove a small sample from the suspected area, so that it can be examined under a microscope. Not ...

Prior treatments included topical and oral ... the labia majora and the vulva showed chronic dermatitis and lichen simplex chronicus. The patient denied having used tampons, pads, douches, condoms ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision ...

Priority Review is granted to regulatory applications seeking approval for therapies that have the potential to provide significant improvements in the treatment, diagnosis or prevention of ...

Treatments may relieve symptoms ... as this may contribute to a condition called lichen simplex chronicus which can further exacerbate the itching sensation There’s no single timeline for ...